June 10, 2021 -- Codexis has expanded its strategic collaboration and license agreement with Takeda Pharmaceutical for the research and development of an additional gene therapy for a lysosomal storage disorder, bringing the total number of programs under the agreement to four.
Under the original agreement, Codexis used its CodeEvolver protein engineering platform to generate novel gene sequences that encode enzyme variants with enhanced efficacy. Subsequently, Takeda has combined the improved transgenes with its gene therapy capabilities to develop novel candidates for the treatment of rare genetic disorders.
Takeda had the contractual option to expand the collaboration into a fourth program. Codexis is responsible for the creation of novel enzyme sequences for advancement as gene therapies into preclinical development.
Takeda is responsible for the preclinical and clinical development and commercialization of gene therapy products resulting from the collaboration programs. Codexis is eligible to receive an upfront payment, reimbursement for research and development fees, development and commercial milestone payments, and royalties in the low- to mid-single-digits on sales of any commercial products developed through the program.